ArticleThe Journal of urology2013
CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth.
Article in The Journal of urology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 92 citations in OpenAlex.
- Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Trial
- Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.Journal of hematology & oncology · 2016Trial
- Selinexor in Uveal Melanoma: A Hopeful Step or Just Another Hurdle?Journal of immunotherapy and precision oncology · 2025Article
- A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma.Journal of immunotherapy and precision oncology · 2024Article
- Michael Acceptors as Anti-Cancer Compounds: Coincidence or Causality?International journal of molecular sciences · 2024Review
- The nuclear export protein exportin-1 in solid malignant tumours: From biology to clinical trials.Clinical and translational medicine · 2024Review
- Therapeutic targeting of nuclear export and import receptors in cancer and their potential in combination chemotherapy.IUBMB life · 2024Review
- CRM1 expression: association with high prognostic value in laryngeal cancer.Turkish journal of medical sciences · 2023Article
- Selective nuclear export inhibitor KPT‑330 enhances the radiosensitivity of esophageal carcinoma cells.Experimental and therapeutic medicine · 2023Article
- A general method for quantitative fractionation of mammalian cells.The Journal of cell biology · 2023Article
- Pan-cancer analysis reveals the roles of XPO1 in predicting prognosis and tumorigenesis.Translational cancer research · 2021Article
- XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor.Journal of experimental & clinical cancer research : CR · 2021Article
- The significance of gradient expression of chromosome region maintenance protein 1 (exportin1) in large cell lymphoma.Haematologica · 2021Article
- MAPS: machine-assisted phenotype scoring enables rapid functional assessment of genetic variants by high-content microscopy.BMC bioinformatics · 2021Article
- Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma.Cancer research · 2020Article
- Doublecortin undergo nucleocytoplasmic transport via the RanGTPase signaling to promote glioma progression.Cell communication and signaling : CCS · 2020Article
- Small Molecule Inhibitors of CRM1.Frontiers in pharmacology · 2020Review
- The past, present, and future of CRM1/XPO1 inhibitors.Stem cell investigation · 2019Review
- Chitosan-based nanoparticles with damnacanthal suppress CRM1 expression.Oncology letters · 2018Article
- Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor.Scientific reports · 2018Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
purposeRenal cell carcinoma often presents asymptomatically and patients are commonly diagnosed at the metastatic stage, when treatment options are limited and survival is poor. Since progression-free survival using current therapy for metastatic renal cell carcinoma is only 1 to 2 years and existing drugs are associated with a high resistance rate, new pharmacological targets are needed. We identified and evaluated the nuclear exporter protein CRM1 as a novel potential therapy for renal cell carcinoma. MATERIALS AND
methodsWe tested the efficacy of the CRM1 inhibitors KPT-185 and 251 in several renal cell carcinoma cell lines and in a renal cell carcinoma xenograft model. Apoptosis and cell cycle arrest were quantified and localization of p53 family proteins was assessed using standard techniques.
resultsKPT-185 attenuated CRM1 and showed increased cytotoxicity in renal cell carcinoma cells in vitro with evidence of increased apoptosis as well as cell cycle arrest. KPT-185 caused p53 and p21 to remain primarily in the nucleus in all renal cell carcinoma cell lines, suggesting that the mechanism of action of these compounds depends on tumor suppressor protein localization. Furthermore, when administered orally in a high grade renal cell carcinoma xenograft model, the bioavailable CRM1 inhibitor KPT-251 significantly inhibited tumor growth in vivo with the expected on target effects and no obvious toxicity.
conclusionsThe CRM1 inhibitor protein family is a novel therapeutic target for renal cell carcinoma that deserves further intensive investigation for this and other urological malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.